US20200230259A1 - Isolation of extracellular vesicles (evs) from red blood cells for gene therapy - Google Patents
Isolation of extracellular vesicles (evs) from red blood cells for gene therapy Download PDFInfo
- Publication number
- US20200230259A1 US20200230259A1 US16/825,097 US202016825097A US2020230259A1 US 20200230259 A1 US20200230259 A1 US 20200230259A1 US 202016825097 A US202016825097 A US 202016825097A US 2020230259 A1 US2020230259 A1 US 2020230259A1
- Authority
- US
- United States
- Prior art keywords
- evs
- cells
- target cells
- rna
- aso
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003743 erythrocyte Anatomy 0.000 title claims abstract description 117
- 238000001415 gene therapy Methods 0.000 title description 5
- 238000002955 isolation Methods 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims abstract description 201
- 238000000034 method Methods 0.000 claims abstract description 46
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 45
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 35
- 201000011510 cancer Diseases 0.000 claims abstract description 22
- 238000004520 electroporation Methods 0.000 claims abstract description 16
- 238000000746 purification Methods 0.000 claims abstract description 12
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 59
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 59
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 32
- 108091091360 miR-125b stem-loop Proteins 0.000 claims description 31
- 108091033409 CRISPR Proteins 0.000 claims description 29
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 28
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 24
- 108020004999 messenger RNA Proteins 0.000 claims description 22
- 229920002307 Dextran Polymers 0.000 claims description 20
- 108020005004 Guide RNA Proteins 0.000 claims description 19
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 18
- 206010006187 Breast cancer Diseases 0.000 claims description 16
- 208000026310 Breast neoplasm Diseases 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 16
- 208000032839 leukemia Diseases 0.000 claims description 15
- 239000013612 plasmid Substances 0.000 claims description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 238000010362 genome editing Methods 0.000 claims description 8
- 239000003710 calcium ionophore Substances 0.000 claims description 7
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 claims description 7
- 230000003042 antagnostic effect Effects 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 231100000590 oncogenic Toxicity 0.000 claims description 5
- 230000002246 oncogenic effect Effects 0.000 claims description 5
- 238000005199 ultracentrifugation Methods 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 238000007910 systemic administration Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 25
- 108020004459 Small interfering RNA Proteins 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 22
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 18
- 239000013642 negative control Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 102000007513 Hemoglobin A Human genes 0.000 description 9
- 108010085682 Hemoglobin A Proteins 0.000 description 9
- 108091044988 miR-125a stem-loop Proteins 0.000 description 9
- 108091049513 miR-125a-1 stem-loop Proteins 0.000 description 9
- 108091040046 miR-125a-2 stem-loop Proteins 0.000 description 9
- 210000001808 exosome Anatomy 0.000 description 8
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 238000003197 gene knockdown Methods 0.000 description 5
- 239000002555 ionophore Substances 0.000 description 5
- 230000000236 ionophoric effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 101100165655 Arabidopsis thaliana BRO1 gene Proteins 0.000 description 3
- 102100032305 Bcl-2 homologous antagonist/killer Human genes 0.000 description 3
- 101000798320 Homo sapiens Bcl-2 homologous antagonist/killer Proteins 0.000 description 3
- 101100082597 Homo sapiens PDCD6IP gene Proteins 0.000 description 3
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 102100033344 Programmed cell death 6-interacting protein Human genes 0.000 description 3
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 101000578351 Homo sapiens Nodal modulator 1 Proteins 0.000 description 2
- 102100027968 Nodal modulator 1 Human genes 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 108020004688 Small Nuclear RNA Proteins 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000003235 crystal violet staining Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000001044 red dye Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000010455 CRISPR delivery Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003095 anti-phagocytic effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000001046 green dye Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012007 large scale cell culture Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108091064282 miR-125 stem-loop Proteins 0.000 description 1
- 108091037066 miR-125-1 stem-loop Proteins 0.000 description 1
- 108091062107 miR-125-2 stem-loop Proteins 0.000 description 1
- 108091079767 miR-125-3 stem-loop Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000002487 multivesicular body Anatomy 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108091008796 oncogenic growth factors Proteins 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
- A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Definitions
- the present invention relates to the field of molecular biology and genome editing, more specifically the transfer of genetic materials to recipient cells by extracellular vesicles (EVs).
- EVs extracellular vesicles
- RNA therapeutics including antisense oligo nucleotides (ASOs), small-interfering RNA (siRNAs), synthetic mRNAs and genome editing RNA-protein complexes are emerging modalities for therapies targeting the human genomes at high specificity and great flexibility.
- ASOs and siRNAs have been widely used as the tools for gene knockdown in biomedical research. Their ability to silence any gene of interest offers a great potential for targeting disease-prevalent genes.
- Various chemical modifications or conjugations can be used to keep ASOs and siRNAs stable and enhance their binding specificity.
- Common methods for RNA transfection including nucleofection, lipofection and electroporation are only suitable for ex vivo delivery. Viral transduction and nanoparticles are often used for in vivo delivery of RNAs and DNAs however, these methods are usually ineffective, immunogenic and toxic.
- CRISPR clustered regularly interspaced short palindromic repeats
- a CRISPR system involves two main components: a Cas9 enzyme and a guide (gRNA).
- the gRNA contains a targeting sequence for DNA binding and a scaffold sequence for Cas9 binding.
- Cas9 nuclease is often used to “knockout” target genes hence it can be applied for deletion or suppression of oncogenes that are essential for cancer initiation or progression.
- CRISPR system offers a great flexibility in targeting any gene of interest hence, potential CRISPR based therapies can be designed based on the genetic mutation in individual patients.
- An advantage of the CRISPR system is its ability to completely ablate the expression of disease genes which can only be suppressed partially by RNA interference methods with ASOs or siRNAs.
- multiple gRNAs can be employed to suppress or activate multiple genes simultaneously, hence increasing the treatment efficacy and reducing resistance potentially caused by new mutations in the target genes.
- the applications of CRISPR technology have evolved very quickly from bench to bedside targeting different diseases. Clinical trials of CRISPR-mediated modification of T cells for cancer therapies have started in China and in the USA. Many other CRISPR-based therapies are under development. However, most of these therapies rely on ex vivo modification of the target cells or systemic delivery of the CRISPR system using virus or nanoparticles that can target very few cell types such as hepatocytes.
- AML Acute myeloid leukemia
- PB peripheral blood
- BM bone marrow
- RNA interference and genome editing methods are emerging as new approaches to target these abnormalities.
- delivery of RNAs to AML cells for gene therapies has proven challenging, especially for in vivo treatments.
- Common gene therapy delivery vehicles such as adeno-associated virus (AAV) and lipid nanoparticles (LNPs) are mostly ineffective or toxic in AML models.
- AAV adeno-associated virus
- LNPs lipid nanoparticles
- RNA delivery to target cells comprising the steps of: a) purification of extracellular vesicles (EVs) from red blood cells (RBCs); b) electroporation of the EVs with RNAs to form RNA-loaded EVs; and c) applying the RNA-loaded EVs to the target cells.
- EVs extracellular vesicles
- RBCs red blood cells
- the advantage of using EVs (including microvesicles and exosomes) from RBCs is that the RBCs are the most abundant blood cells hence a large amount of EVs can be obtained and purified from RBC units that are available at any blood bank.
- the RBCs are derived from a human. They are also nontoxic, unlike synthetic transfection reagents.
- RBC EVs do not contain oncogenic DNA/RNA or growth factors that are usually abundant in EVs from cancer cells or stem cells, hence RBC EVs do not post any transformation risks to recipient cells.
- the RBCs are derived from a mammal preferably a human and treated with ionophore in particular calcium ionophore.
- the EVs are purified using ultracentrifugation with a sucrose cushion.
- sucrose cushion refers to a sucrose gradient which establishes itself during a centrifugation.
- the sucrose gradient is prepared by using a solution of about 40% to about 70%, about 50% to about 60%, or about 60% of sucrose.
- the electroporated EVs comprises antisense oligonucleotides (ASO), mRNAs and plasmids.
- ASO antisense oligonucleotides
- mRNAs mRNAs
- plasmids plasmids.
- the ASO comprises or consists of SEQ ID NO: 1.
- the target cells comprise cancer cells, or are cancer cells.
- the target cells comprise leukemia cells in particular acute myeloid leukemia (AML) cells, breast cancer cells, or a combination of AML cells and breast cancer cells.
- AML acute myeloid leukemia
- the EVs are electroporated with ASO antagonizing miR-125b for knockdown of miR-125b in target cells as described above.
- the ASO antagonizing miR-125b comprises or consists of SEQ ID NO: 1.
- the growth of the target cells is suppressed.
- the EVs are electroporated with a small chemical such as dextran.
- the method comprises administering to the target cells the RNA-loaded EVs which modulate an apoptosis-related gene expression, thereby inducing apoptosis in the target cells.
- a method for delivery of an antisense oligonucleotide (ASO) to target cells to suppress gene expression comprising the steps of: a) purification of extracellular vesicles (EVs) from red blood cells (RBCs); b) electroporation of the EVs with RNAs to form RNA-loaded EVs; and c) applying the RNA-loaded EVs to the target cells.
- ASO antisense oligonucleotide
- the RBCs are derived from a mammal preferably a human, and treated with ionophore in particular calcium ionophore.
- the RNA is an ASO antagonizing miR-125b to inhibit the oncogenic miR-125b in the target cells.
- the ASO antagonizing miR-125b comprises or consists of SEQ ID NO: 1.
- the target cells comprise cancer cells or are cancer cells.
- the target cells comprise leukemia cells in particular AML, cells, breast cancer cells, or a combination of AML cells and breast cancer cells.
- a method of RNA delivery to target cells for a CRISPR genome editing system comprising the steps of: a) purification of extracellular vesicles (EVs) from red blood cells (RBCs), wherein the RBCs are preferably derived from a human and treated with ionophore in particular calcium ionophore; b) electroporation of the EVs with RNAs which may be Cas9 mRNAs and/or gRNAs to form RNA-loaded EVs; and c) applying the RNA-loaded EVs to the target cells.
- CRISPR is a method that enables robust and precise modifications of genomic DNA for a wide range of applications in research and medicine. The system can be designed to target genomic DNA directly.
- the EVs are electroporated with Cas9 mRNA and gRNA.
- Cas9 mRNA comprises or consists of SEQ ID NO: 2.
- the gRNA is eGFP gRNA comprising or consisting of SEQ ID NO: 3.
- the EVs are electroporated with Cas9 and gRNA plasmids.
- the target cells comprise cancer cells or are cancer cells.
- the target cells comprise leukemia cells or are leukemia cells.
- the target cells comprise leukemia cells in particular AML cells, breast cancer cells, or a combination of AML cells and breast cancer cells.
- a method of treating cancer by delivery of RNA to target cells comprising the steps of: a) purification of extracellular vesicles (EVs) from red blood cells (RBCs) which are preferably derived from a mammal in particular a human and treated with ionophore in particular calcium ionophore; b) electroporation of the EVs with RNAs to form RNA-loaded EVs; and c) applying the RNA-loaded EVs to the target cells thereby inhibiting the growth of the target cells, wherein the target cells comprise cancer cells.
- EVs extracellular vesicles
- RBCs red blood cells
- the target cells comprise leukemia cells, breast cancer cells, or a combination of leukemia cells and breast cancer cells. In another embodiment, the target cells comprise acute myeloid leukemia cells.
- the step c) comprises a step of administering the RNA-loaded EVs to a subject having the target cells via a local or systemic administration.
- Local administration refers to the delivery of the RNA-loaded EVs directly to the site of action, and includes, but not limiting to, intratumoral administration.
- Systemic administration refers to the delivery of the RNA-loaded EVs via circulatory system, and includes, but not limiting to, intravenous injection.
- the growth of the target cells is suppressed after the step c).
- FIG. 1 a is a schematic diagram showing the process of collecting the Evs from human red blood cells (RBCs).
- FIG. 1 b is a plot showing the concentration and the size distribution of RBC EVs.
- FIG. 1 c shows the expression of ALIX, TSG101, and hemoglobin A in cell lysates and EVs, via Western blot analysis.
- FIG. 2 a is a schematic presentation of EV electroporation.
- FIG. 2 b show the results obtained from FACS analysis of AF647 fluorescence and forward scatter (FSC) of the beads that were incubated with electroporated EVs (E-EVs) or unelectroporated EVs (UE-EVs).
- FSC fluorescence and forward scatter
- FIG. 3 a is a schematic presentation of the EV uptake assay.
- FIG. 3 b shows the expression of HBA relative to GAPDH, via Western blot analysis.
- FIG. 3 c shows the uptake of RBC EVs by leukemia MOLM13 cells, via FACS analysis.
- FIG. 4 a is a schematic presentation of Dextran delivery.
- FIG. 4 b shows RBC EVs deliver dextran to leukemia MOLM13 cells, via FACS analysis.
- FIG. 5 a is a schematic presentation of ASO delivery.
- FIG. 5 b shows the results obtained from FACS analysis, where the MOLM13 cells were untreated or incubated with FAM ASO or with electroporated EVs (E-EVs) or with unelectroporated EVs (UE-EVs).
- FIG. 5 c is a plot showing the results of FIG. 5 b .
- FIG. 5 d is a diagram showing the average percentage of FAM-positive cells after treatments. In particular, the results reveal that RBC EVs deliver antisense oligonucleotides (ASO) to leukemia MOLM13 cells.
- ASO antisense oligonucleotides
- FIG. 6 a shows the results obtained from FACS analysis of AF647 fluorescence in MOLM13 cells that were untreated, incubated with Dextran AF647 (Dex-647) alone, with Dex-647 and unelectroporated RBC EVs (UE-EVs), with Dex-647 loaded LipofectaminTM 3000 (Lipo3000), with Dex-647 loaded INTERFERin or with Dex-647 electroporated RBC EVs (E-EVs) for 24 hours.
- UE-EVs Dex-647 loaded LipofectaminTM 3000 (Lipo3000)
- E-EVs Dex-647 loaded INTERFERin
- 6 b shows the results obtained from FACS analysis of FAM fluorescence in MOLM13 cells that were untreated, incubated with FAM-ASO alone, with FAM-ASO and unelectroporated RBC EVs (UE-EVs), with FAM-ASO loaded Lipo3000, with FAM-ASO loaded INTERFERin or with FAM-ASO electroporated RBC EVs (E-EVs) for 24 hours.
- UE-EVs FAM-ASO loaded Lipo3000
- E-EVs FAM-ASO electroporated RBC EVs
- FIG. 7 a shows the percentage of cell death/viability of MOLM13 cells after treatments with Dextran AF647 (Dex-647) alone, with Dex-647 and unelectroporated RBC EVs (UE-EVs), with Dex-647 loaded LipofectaminTM 3000 (Lipo3000), with Dex-647 loaded INTERFERin or with Dex-647 electroporated RBC EVs (E-EVs) for 24 hours.
- Dextran AF647 Dex-647
- UE-EVs Dex-647 and unelectroporated RBC EVs
- Dex-647 loaded LipofectaminTM 3000 Lipo3000
- Dex-647 loaded INTERFERin or with Dex-647 electroporated RBC EVs (E-EVs) for 24 hours.
- FIG. 7 a shows the percentage of cell death/viability of MOLM13 cells after treatments with Dextran AF647 (Dex-647) alone, with Dex-647 and une
- 7 b shows the percentage of cell death/viability of MOLM13 cells after treatments with FAM-ASO alone, with FAM-ASO and unelectroporated RBC EVs (UE-EVs), with FAM-ASO loaded Lipo3000, with FAM-ASO loaded INTERFERin or with FAM-ASO electroporated RBC EVs (E-EVs) for 24 hours
- FIG. 8 a is a schematic presentation of miR-125b ASO delivery.
- FIG. 8 b shows the expression of miR-125b in MOLM13 cells after treatment with unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours.
- UE-EVs unelectroporated RBC EVs
- NC negative control
- E-EVs negative control
- 125b-ASO anti-miR-125b ASO
- FIG. 8 c shows the expression of miR-125a in MOLM13 cells after treatment with unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours.
- FIG. 8 d shows the expression of BAK1 relative to GAPDH in MOLM13 cells treated the same as in FIGS. 8 b and 8 c .
- FIG. 8 e shows the number of MOLM13 cells untreated, or treated with UE-EVs or with ASO electroporated EVs as indicated.
- FIG. 9 a is a schematic presentation of miR-125b ASO delivery.
- FIG. 9 b shows the expression of miR-125b in CA1a cells after treatment with unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours.
- UE-EVs unelectroporated RBC EVs
- NC negative control
- E-EVs negative control
- 125b-ASO anti-miR-125b ASO
- FIG. 9 c shows the expression of miR-125a in CA1a cells after treatment with unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours.
- FIG. 9 d shows the results of crystal violet staining of CA1a cells after treatments as indicated above.
- FIG. 10 a is a schematic presentation of Cas9 mRNA delivery.
- FIG. 10 b shows the levels of Cas9 mRNA in MOLM13 cells after treatment with unelectroporated EVs or with EVs that were electroporated with 5, 10 or 20 ⁇ g Cas9 mRNA, determined by qRT-PCR after 24 hours of treatment.
- FIG. 10 c show representative images of MOLM13 cells after treatments as indicated above.
- FIG. 10 d shows the average percentage of MOLM13 cells stained positive for HA-Cas9 protein as shown in FIG. 10 c.
- FIG. 11 a is a schematic presentation of the RNA delivery.
- FIG. 11 b shows the results obtained from FACS analysis of GFP in NOMO1-GFP cells after treatment with unelectroporated EVs or EVs electroporated with Cas9 and gRNA.
- FIG. 12 a is a schematic presentation of plasmid delivery.
- FIG. 12 b shows the results obtained from FACS analysis of GFP in 293T-eGFP cells untreated, or incubated with unelectroporated EVs (UE-EVs) or with plasmid electroporated EVs (E-EVs) as indicated.
- FIG. 12 c shows the plot prepared from the results of FIG. 12 b.
- FIG. 13 a is a schematic presentation of an in vivo EV uptake assay.
- FIG. 13 b shows the fluorescent images of nude mice bearing untreated tumors on the right and tumors injected with PKH26-labeled EVs on the left.
- FIG. 13 c shows the ex vivo fluorescent images of the tumors at 72 hours post-treatment.
- FIG. 13 d shows the total radiance efficiency (photons/second) of fluorescent signals in the tumors 24-72 hours after the injection of PKH26-labeled EVs.
- the present invention relates to the field of molecular biology and genome editing. More specifically the transfer of genetic materials to recipient cells by extracellular vesicles (EVs) and the method of purification or isolation of exosomes from Red Blood Cells.
- EVs extracellular vesicles
- EVs Extracellular vesicles
- EVs secreted by many cell types contain RNAs that function to alter the phenotypes of other cells.
- EVs contain not only RNAs but also proteins that stabilize RNAs and facilitate the functions of RNAs in the target cells.
- EV-mediated delivery of RNAs is an attractive platform because the natural biocompatibility of EVs is the solution to overcome most in vivo delivery hurdles.
- EVs are generally nontoxic and non-immunogenic. They are taken up readily by many cell types but they do possess some antiphagocytic markers such as CD47 that help them to evade the phagocytosis by macrophages of the reticuloendothelial system.
- EVs are able to extravasate well through the interendothelial junctions and even cross the blood-brain barrier hence, they are greatly versatile drug carriers.
- delivery by EVs is not hampered by the multidrug resistance mechanism caused by overexpression of P-glycoproteins that tumor cells often exhibit to eliminate many chemical compounds.
- EVs from cancer cell lines and stem cells which are very costly due to the large-scale cell culture that requires various supplements.
- EVs from cancer and stem cells may contain oncogenic proteins or growth factors that promote cancer growth.
- EVs from plasma and blood cells are safer for cancer therapies.
- RBCs EVs do not contain oncogenic DNA/RNA or growth factors that are usually abundant in EVs from cancer cells or stem cells, hence, RBC EVs do not post any transformation risks to recipient cells.
- RBCs EVs are also nontoxic unlike synthetic transfection reagents.
- an RNA is selected to inhibit expression of a target gene by binding to a miRNA or editing the target genomic DNA. Further, there is provided a novel method for the purification of EVs from red blood cells (RBCs) and incorporation of RNAs in EVs for gene therapies against cancer, including acute myeloid leukemia and breast cancer.
- RBCs red blood cells
- RBCs Blood samples were obtained by Red Cross from healthy donors in Hong Kong with informed consents.
- RBCs were separated from plasma and white blood cells by centrifugation and treated with 10 mM calcium ionophore (Sigma) overnight.
- the purification of EVs were optimized with multiple centrifugation steps including the removal of protein contamination using a 60% sucrose cushion (ultracentrifugation at 100,000 ⁇ g) that yields a homogenous population of EVs with an average diameter of ⁇ 140 nm.
- These EVs are enriched in EV markers, ALIX and TSG101, as shown by Western blot analysis. They also contain hemoglobin A which is a major protein from RBCs.
- FIG. 1 a Culture supernatants were collected from ionophore-treated human red blood cells and subjected to multiple steps of centrifugation to remove dead cells and debris. EVs were purified by ultracentrifugation with 60% sucrose cushion and washed with phosphate buffer saline (PBS) by ultracentrifugation (100,000 ⁇ g).
- FIG. 1 b Concentrations and the size distribution of RBC EVs were measured by a Nanosight nanoparticle analyzer.
- FIG. 1 c Western blot analysis of ALIX, TSG101 (EV markers) and Hemoglobin A (RBC marker) relative to GAPDH in the cell lysate and EVs purified from RBCs.
- an electroporation protocol was optimized for the RBC EVs using Dextran conjugated with Alexa Fluor® 647 (AF647, Thermo Fisher Scientific) tested at different voltages using a Gene Pulser Xcell electroporator (BioRad). Electroporated EVs were added to latex beads and analyzed for AF647 using flow cytometry. It was found that 250 V was the optimal voltage, which resulted in 93.6% AF647 positive EV-bound beads.
- FIG. 2 a Schematic presentation of EV electroporation: 50 ⁇ g RBC EVs were mixed with 4 ⁇ g Alexa Fluor® 647 (AF647) labeled Dextran and electroporated at different voltages from 50 to 250 V. EVs were incubated with latex beads overnight and analyzed by fluorescent activated cell sorting (FACS).
- FIG. 2 b FACS analysis of AF647 fluorescence and forward scatter (FSC) of the beads that were incubated with electroporated EVs (E-EVs) or unelectroporated EVs (UE-EVs). The percentage of AF647 positive beads are indicated above the gates.
- FSC fluorescent activated cell sorting
- the RBC-derived EVs was labelled with a fluorescent membrane dye called Bodipy® TR (Thermo Fisher). Labeled EVs were washed extensively using the sucrose cushion, mock electroporated and added to the AML MOLM13 cells. After 24 hours of incubation with EVs, Western blot analysis of MOML13 cells showed a clear uptake of Hemoglobin A (HBA) protein which was absent in the untreated cells. Importantly, treatment with RBC EVs did not affect the viability of AML cells as shown by FACS analysis.
- HBA Hemoglobin A
- MOLM13 cells became 100% Bodipy positive after the incubation with Bodipy-labeled EVs, indicating that all the cells took up the fluorescent RBC EVs. Electroporation increased the uptake of HBA but not Bodipy by MOLM13 cells.
- FIG. 3 a Schematic presentation of the EV uptake assay: 50 ⁇ g RBC EVs were labeled with Bodipy TR (a red fluorescent dye), washed twice, mock electroporated at 250 V, and incubated with MOLM13 cells for 24 hours.
- FIG. 3 b Western blot analysis of hemoglobin A (HBA) relative to GAPDH and
- FIG. 3 c FACS analysis of live cells, gated based on size scatter (SSC) and forward scatter (FSC), and BODIPY fluorescence in MOLM13 cells that were untreated or incubated with electroporated EVs (E-EVs) or unelectroporated EVs (UE-EVs).
- SSC size scatter
- FSC forward scatter
- FIG. 4 a Schematic presentation of Dextran delivery: 50-100 ⁇ g RBC EVs were mixed with 4 ⁇ g Dextran AF647 and electroporated at 250 V. Electroporated EVs were incubated with MOLM13 cells for 24 hours.
- FIG. 4 b FACS analysis of Dextran AF647 fluorescence in MOLM13 cells that were untreated or incubated with 50-100 ⁇ g Dextran AF647 electroporated EVs (E-EVs) or 100 ⁇ g unelectroporated (UE-EVs).
- E-EVs E-EVs
- UE-EVs unelectroporated
- RNA oligonucleotide green fluorescent labeled scrambled RNA oligonucleotide (Shanghai GenePharma), about 7 kDa, that is often used as a negative control antisense oligonucleotide (ASO).
- FAM green fluorescent labeled scrambled RNA oligonucleotide
- MOLM13 cells MOLM13 cells
- FIG. 5 a Schematic presentation of ASO delivery: 75 ⁇ g RBC EVs were electroporated with 400 pmole FAM fluorescent labeled scrambled ASO ( ⁇ 7 kDa) and incubated with MOLM13 cells for 24 hours.
- FIGS. 5 b -5 d FACS analysis of FAM fluorescence in MOLM13 cells that were untreated or incubated with FAM ASO or with electroporated EVs (E-EVs) or with unelectroporated EVs (UE-EVs). The average percentage+SEM of FAM-positive cells were calculated from 3 independent experiments as shown in FIG. 5 d.
- Dextran AF647 and FAM ASO were then compared with that of two commercialized lipofection reagents, LipofectamineTM 3000 (Thermo Fisher Scientific) and INTERFERinTM (Polyplus transfection) that are commonly used for transfection of nucleic acids in mammalian cells. Consistent with previous experiments, RBC EVs delivered Dextran AF647 and FAM ASO to ⁇ 75% MOLM13 cells. LipofectamineTM 3000 archived only 3% and 55% delivery of Dextran AF647 and FAM ASO whereas INTERFERin archived only 2.7% and 38.7% delivery of Dextran AF647 and FAM ASO respectively in MOML13 cells.
- LipofectamineTM 3000 and INTERFERin were not a surprise since blood cells including AML cells are referred to as “difficult-to-transfect” cell types by the manufacturers. Hence, the 75% delivery efficiency archived by RBC EVs was a great improvement.
- FIG. 6 a FACS analysis of AF647 fluorescence in MOLM13 cells that were untreated, incubated with 4 ⁇ g Dextran AF647 (Dex-647) alone, with Dex-647 and unelectroporated RBC EVs (UE-EVs), with Dex-647 loaded LipofectaminTM 3000 (Lipo3000), with Dex-647 loaded INTERFERin or with Dex-647 electroporated RBC EVs (E-EVs) for 24 hours.
- UE-EVs Dex-647 loaded LipofectaminTM 3000 (Lipo3000)
- E-EVs Dex-647 loaded INTERFERin
- 6 b FACS analysis of FAM fluorescence in MOLM13 cells that were untreated, incubated with 2 ⁇ mole FAM-ASO alone, with FAM-ASO and unelectroporated RBC EVs (UE-EVs), with FAM-ASO loaded Lipo3000, with FAM-ASO loaded INTERFERin or with FAM-ASO electroporated RBC EVs (E-EVs) for 24 hours.
- UE-EVs FAM-ASO and unelectroporated RBC EVs
- E-EVs FAM-ASO electroporated RBC EVs
- RBC EVs exhibit no toxicity to the cells in contrast to about 20-30% increase in cell death caused by the transfection using LipofectamineTM 3000 and INTERFERin.
- FIG. 7 a MOLM13 cells that were untreated, incubated with 4 ⁇ g Dextran AF647 (Dex-647) alone, with Dex-647 and unelectroporated RBC EVs (UE-EVs), with Dex-647 loaded LipofectaminTM 3000 (Lipo3000), with Dex-647 loaded INTERFERin or with Dex-647 electroporated RBC EVs (E-EVs) for 24 hours;
- PI Propidium iodide
- miR-125b is upregulated in different types of cancer including AML and other leukemia. It has been shown that miR-125b suppresses apoptosis by regulating multiple genes in the p53 network. miR-125b also promotes proliferation of hematopoietic stem cells and leukemia cells in both humans and mouse models.
- An anti-miR-125b ASO (Shanghai Gene Pharma) comprising a sequence of SEQ ID NO: 1 was loaded into RBC EVs using electroporation and treated MOLM13 cells with these EVs.
- miR-125b the level of miR-125b was suppressed by 80-95% in a dose-dependent manner.
- miR-125a the homologue of miR-125b, was also suppressed by 50-80% due to the sequence similarity to miR-125b.
- Inhibition of miR-125 led to a significant increase in BAK1, a target of miR-125a/b which regulates apoptosis.
- Treatment with miR-125b ASO loaded EVs also dampened the growth of MOLM13 cells significantly after 3-4 days of incubation. Hence, the inhibition of miR-125b using ASO in RBC EVs may represent a new approach for AML treatment.
- miR-125b preferably comprises or consists of SEQ ID NO: 4 and miR-125a preferably comprises or consists of SEQ ID NO: 5.
- miR-125b consists of SEQ ID NO: 4 and miR-125a consists of SEQ ID NO: 5.
- FIG. 8 a Schematic presentation of miR-125b ASO delivery: 25-100 ⁇ g RBC EVs were electroporated with 2 ⁇ mole anti-miR-125b ASO and incubated with MOLM13 cells.
- Anti-miR-125b ASO in this embodiment consists of SEQ ID NO: 1.
- FIGS. 8 a Schematic presentation of miR-125b ASO delivery: 25-100 ⁇ g RBC EVs were electroporated with 2 ⁇ mole anti-miR-125b ASO and incubated with MOLM13 cells.
- Anti-miR-125b ASO in this embodiment consists of SEQ ID NO: 1.
- FIG. 8 b - c Expression of miR-125b and miR-125a relative to U6b snRNA in MOLM13 cells that were untreated, incubated with 100 ug unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours, as determined by Taqman qRT-PCR, presented as average and SEM.
- FIG. 8 d Expression of BAK1 relative to GAPDH in MOLM13 cells treated the same as in FIG. 8 b .
- FIG. 8 e Number of MOLM13 cells untreated, or treated with UE-EVs or with ASO electroporated EVs as indicated.
- One-way Anova test ** P ⁇ 0.01; *** P ⁇ 0.001.
- RBC EVs were tested for the delivery of miR-125b ASO to breast cancer MCF10aCA1a (CA1a) cells.
- the inventors observed 80-90% knockdown of miR-125a and miR-125b in CA1a cells treated with miR-125b ASO loaded EVs. As a consequence, the knockdown of miR-125s suppressed the proliferation of CA1a cells.
- FIG. 9 a Schematic presentation of miR-125b ASO delivery: 25-50 ⁇ g RBC EVs were electroporated with 2 ⁇ mole anti-miR-125b ASO and incubated with CA1a cells.
- FIG. 9 b - c Expression of miR-125b and miR-125a relative to U6b snRNA in CA1a cells that were untreated, incubated with unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours, as determined by Taqman qRT-PCR, presented as average and SEM.
- UE-EVs unelectroporated RBC EVs
- NC negative control
- E-EVs negative control
- E-EVs anti-miR-125b ASO
- 125b-ASO anti-mi
- FIG. 10 a Schematic presentation of Cas9 mRNA delivery: RBC EVs were electroporated with Cas9 mRNA and incubated with MOLM13 cells for 24 or 48 hours.
- FIG. 10 a Schematic presentation of Cas9 mRNA delivery: RBC EVs were electroporated with Cas9 mRNA and incubated with MOLM13 cells for 24 or 48 hours.
- FIG. 10 b The levels of Cas9 mRNA relative to GAPDH mRNA in MOLM13 cells that were untreated, incubated with unelectroporated EVs or with EVs that were electrop
- FIG. 10 c Representative images of MOLM13 cells that were untreated, or incubated for 48 hours with unelectroporated EVs or with EVs that were electroporated with 10 ⁇ g Cas9 mRNAs. The cells were stained for HA-Cas9 protein (using green dye, not seen in black and white images) and nuclear DNA (Hoechst, blue dye, not seen in black and white images).
- FIG. 10 d Average percentage of MOLM13 cells stained positive for HA-Cas9 protein as shown in (c).
- Cas9 mRNA preferably comprises or consists of SEQ ID NO: 2 and eGFP gRNA preferably comprises or consists of SEQ ID NO: 3.
- Cas9 mRNA consists of SEQ ID NO: 2 and eGFP gRNA consists of SEQ ID NO: 3.
- FIG. 11 a Schematic presentation of the RNA delivery: RBC EVs were electroporated with Cas9 mRNA and anti-GFP gRNA and incubated with NOMO1-GFP cells for 7 days.
- FIG. 11 b FACS analysis of GFP in NOMO1-GFP cells that were untreated, incubated with unelectroporated EVs or EVs electroporated with Cas9 and gRNA. The percentages of GFP-negative cells are shown above the gate.
- RBC EVs were electroporated with two plasmids, one expressing SpCas9 and one expressing gRNA against eGFP. Electroporated EVs were incubated with human embryonic kidney HEK-293T cells that homogenously express eGFP. After 96 hours, it was found that 13.8% GFP-negative cells resulted from the EV treatment, compared to 3.52% GFP-negative in the untreated population. Treatment with electroporated EVs showed a distinct peak of GFP-negative cells that suggests a homologous knockout of eGFP by the delivery of Cas9 and gRNA plasmids. Therefore, RBC EVs are able to deliver not only RNA but also plasmid DNA for genome editing. Moreover, the delivery is applicable to HEK-293T solid cancer cells.
- FIG. 12 a Schematic presentation of plasmid delivery: RBC EVs were electroporated with Cas9 plasmid and eGFP gRNA plasmid and incubated with eGFP expressing 293T cells for 96 hours.
- FIGS. 12 b -12 c FACS analysis of GFP in 293T-eGFP cells untreated, or incubated with unelectroporated EVs (UE-EVs) or with plasmid electroporated EVs (E-EVs) as indicated.
- the GFP negative cells are indicated by the percentages in FIG. 12 b and the arrow in FIG. 12 c.
- FIG. 13 a Schematic presentation of an in vivo EV uptake assay.
- FIG. 13 b Fluorescent images of nude mice bearing untreated tumors on the top and tumors injected with PKH26-labeled (red dye, not seen in black and white images) EVs on the bottom.
- FIG. 13 c Ex vivo fluorescent images of the tumors at 72 hours post-treatment.
- FIG. 13 d Total radiance efficiency (photons/second) of fluorescent signals in the tumors 24-72 hours after the injection of PKH26-labeled EVs.
- CA1a cells were implanted in the mice, in the flank at 2 sides ( FIG.
- FIG. 13 a shows ex vivo fluorescent images of the tumors at 72 hours post-treatment and proves that PKH26-labeled EVs were taken up by tumor cells.
- the total radiance efficiency (photons/second) of fluorescent signals in the tumors decreased gradually 24 to 72 hours after the injection of PKH26-labeled EVs as shown in FIG. 13 d.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Ecology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Description
- The Sequence Listing file entitled “sequencelisting” having a size of 6,395 bytes and a creation date of Aug. 16, 2017, that was filed with the patent application is incorporated herein by reference in its entirety.
- The present invention relates to the field of molecular biology and genome editing, more specifically the transfer of genetic materials to recipient cells by extracellular vesicles (EVs).
- RNA therapeutics including antisense oligo nucleotides (ASOs), small-interfering RNA (siRNAs), synthetic mRNAs and genome editing RNA-protein complexes are emerging modalities for therapies targeting the human genomes at high specificity and great flexibility. ASOs and siRNAs have been widely used as the tools for gene knockdown in biomedical research. Their ability to silence any gene of interest offers a great potential for targeting disease-prevalent genes. Various chemical modifications or conjugations can be used to keep ASOs and siRNAs stable and enhance their binding specificity. Common methods for RNA transfection including nucleofection, lipofection and electroporation are only suitable for ex vivo delivery. Viral transduction and nanoparticles are often used for in vivo delivery of RNAs and DNAs however, these methods are usually ineffective, immunogenic and toxic.
- One of the most recent breakthroughs in Science is a new technology for genome editing, the clustered regularly interspaced short palindromic repeats (CRISPR) method that enables robust and precise modifications of genomic DNA for a wide range of applications in research and medicine. CRISPR is an ideal tool for correction of genetic abnormalities in cancer as the system can be designed to target genomic DNA directly. A CRISPR system involves two main components: a Cas9 enzyme and a guide (gRNA). The gRNA contains a targeting sequence for DNA binding and a scaffold sequence for Cas9 binding. Cas9 nuclease is often used to “knockout” target genes hence it can be applied for deletion or suppression of oncogenes that are essential for cancer initiation or progression. Similar to ASOs and siRNAs, the CRISPR system offers a great flexibility in targeting any gene of interest hence, potential CRISPR based therapies can be designed based on the genetic mutation in individual patients. An advantage of the CRISPR system is its ability to completely ablate the expression of disease genes which can only be suppressed partially by RNA interference methods with ASOs or siRNAs. Furthermore, multiple gRNAs can be employed to suppress or activate multiple genes simultaneously, hence increasing the treatment efficacy and reducing resistance potentially caused by new mutations in the target genes. The applications of CRISPR technology have evolved very quickly from bench to bedside targeting different diseases. Clinical trials of CRISPR-mediated modification of T cells for cancer therapies have started in China and in the USA. Many other CRISPR-based therapies are under development. However, most of these therapies rely on ex vivo modification of the target cells or systemic delivery of the CRISPR system using virus or nanoparticles that can target very few cell types such as hepatocytes.
- Acute myeloid leukemia (AML) is the most aggressive type of blood cancer that affects nearly 352,000 people per year with the 5-year prevalence of 1.5%. AML is characterized by the increase of myeloblasts in the peripheral blood (PB) and the bone marrow (BM). 30-40% AML patients (mostly under 60 years old) response well to chemotherapy and hematopoietic stem cell transplantation. However, the response rate is much lower in older patients as they cannot tolerate the toxicity of chemotherapy. Moreover, almost all the patients relapse after a certain time due to drug resistance. Hence, new treatment strategies are desirable to increase the response rate, reduce toxicity and combat drug resistance. Recent advances in genomics have provided better understanding of the genetic and epigenetic abnormalities in AML and suggest new specific therapeutic targets. RNA interference and genome editing methods are emerging as new approaches to target these abnormalities. However, delivery of RNAs to AML cells for gene therapies has proven challenging, especially for in vivo treatments. Common gene therapy delivery vehicles such as adeno-associated virus (AAV) and lipid nanoparticles (LNPs) are mostly ineffective or toxic in AML models.
- Therefore, there is a desire to improve the delivery efficiency and reduce toxicity of gene therapies for cancer.
- In one aspect of the invention, there is provided a method for RNA delivery to target cells comprising the steps of: a) purification of extracellular vesicles (EVs) from red blood cells (RBCs); b) electroporation of the EVs with RNAs to form RNA-loaded EVs; and c) applying the RNA-loaded EVs to the target cells.
- The advantage of using EVs (including microvesicles and exosomes) from RBCs is that the RBCs are the most abundant blood cells hence a large amount of EVs can be obtained and purified from RBC units that are available at any blood bank. Preferably, the RBCs are derived from a human. They are also nontoxic, unlike synthetic transfection reagents. RBC EVs do not contain oncogenic DNA/RNA or growth factors that are usually abundant in EVs from cancer cells or stem cells, hence RBC EVs do not post any transformation risks to recipient cells.
- In one embodiment, the RBCs are derived from a mammal preferably a human and treated with ionophore in particular calcium ionophore. The EVs are purified using ultracentrifugation with a sucrose cushion. The term “sucrose cushion” refers to a sucrose gradient which establishes itself during a centrifugation. In an embodiment, the sucrose gradient is prepared by using a solution of about 40% to about 70%, about 50% to about 60%, or about 60% of sucrose.
- In another embodiment, the electroporated EVs comprises antisense oligonucleotides (ASO), mRNAs and plasmids. Preferably, the ASO comprises or consists of SEQ ID NO: 1.
- In a further embodiment, the target cells comprise cancer cells, or are cancer cells. In another embodiment, the target cells comprise leukemia cells in particular acute myeloid leukemia (AML) cells, breast cancer cells, or a combination of AML cells and breast cancer cells.
- In another embodiment, the EVs are electroporated with ASO antagonizing miR-125b for knockdown of miR-125b in target cells as described above. Preferably, the ASO antagonizing miR-125b comprises or consists of SEQ ID NO: 1.
- In another embodiment, the growth of the target cells is suppressed. In a further embodiment, the EVs are electroporated with a small chemical such as dextran.
- In another embodiment, the method comprises administering to the target cells the RNA-loaded EVs which modulate an apoptosis-related gene expression, thereby inducing apoptosis in the target cells.
- In a second aspect of the invention, there is provided a method for delivery of an antisense oligonucleotide (ASO) to target cells to suppress gene expression, comprising the steps of: a) purification of extracellular vesicles (EVs) from red blood cells (RBCs); b) electroporation of the EVs with RNAs to form RNA-loaded EVs; and c) applying the RNA-loaded EVs to the target cells.
- In an embodiment, as described above, the RBCs are derived from a mammal preferably a human, and treated with ionophore in particular calcium ionophore.
- In one embodiment, the RNA is an ASO antagonizing miR-125b to inhibit the oncogenic miR-125b in the target cells. Preferably, the ASO antagonizing miR-125b comprises or consists of SEQ ID NO: 1.
- In another embodiment, the target cells comprise cancer cells or are cancer cells. In another embodiment, the target cells comprise leukemia cells in particular AML, cells, breast cancer cells, or a combination of AML cells and breast cancer cells.
- In a third aspect of the invention, there is provided a method of RNA delivery to target cells for a CRISPR genome editing system comprising the steps of: a) purification of extracellular vesicles (EVs) from red blood cells (RBCs), wherein the RBCs are preferably derived from a human and treated with ionophore in particular calcium ionophore; b) electroporation of the EVs with RNAs which may be Cas9 mRNAs and/or gRNAs to form RNA-loaded EVs; and c) applying the RNA-loaded EVs to the target cells. CRISPR is a method that enables robust and precise modifications of genomic DNA for a wide range of applications in research and medicine. The system can be designed to target genomic DNA directly.
- In one embodiment, the EVs are electroporated with Cas9 mRNA and gRNA. Preferably, Cas9 mRNA comprises or consists of SEQ ID NO: 2. Further, the gRNA is eGFP gRNA comprising or consisting of SEQ ID NO: 3.
- In another embodiment, the EVs are electroporated with Cas9 and gRNA plasmids. In another embodiment, the target cells comprise cancer cells or are cancer cells.
- In a further embodiment, the target cells comprise leukemia cells or are leukemia cells. In a particular embodiment, the target cells comprise leukemia cells in particular AML cells, breast cancer cells, or a combination of AML cells and breast cancer cells.
- In a fourth aspect of the invention, there is provided a method of treating cancer by delivery of RNA to target cells comprising the steps of: a) purification of extracellular vesicles (EVs) from red blood cells (RBCs) which are preferably derived from a mammal in particular a human and treated with ionophore in particular calcium ionophore; b) electroporation of the EVs with RNAs to form RNA-loaded EVs; and c) applying the RNA-loaded EVs to the target cells thereby inhibiting the growth of the target cells, wherein the target cells comprise cancer cells.
- In one embodiment, the target cells comprise leukemia cells, breast cancer cells, or a combination of leukemia cells and breast cancer cells. In another embodiment, the target cells comprise acute myeloid leukemia cells.
- In another embodiment, the step c) comprises a step of administering the RNA-loaded EVs to a subject having the target cells via a local or systemic administration. Local administration refers to the delivery of the RNA-loaded EVs directly to the site of action, and includes, but not limiting to, intratumoral administration. Systemic administration refers to the delivery of the RNA-loaded EVs via circulatory system, and includes, but not limiting to, intravenous injection.
- In a further embodiment, the growth of the target cells is suppressed after the step c).
-
FIG. 1a is a schematic diagram showing the process of collecting the Evs from human red blood cells (RBCs).FIG. 1b is a plot showing the concentration and the size distribution of RBC EVs.FIG. 1c shows the expression of ALIX, TSG101, and hemoglobin A in cell lysates and EVs, via Western blot analysis. -
FIG. 2a is a schematic presentation of EV electroporation.FIG. 2b show the results obtained from FACS analysis of AF647 fluorescence and forward scatter (FSC) of the beads that were incubated with electroporated EVs (E-EVs) or unelectroporated EVs (UE-EVs). -
FIG. 3a is a schematic presentation of the EV uptake assay.FIG. 3b shows the expression of HBA relative to GAPDH, via Western blot analysis.FIG. 3c shows the uptake of RBC EVs by leukemia MOLM13 cells, via FACS analysis. -
FIG. 4a is a schematic presentation of Dextran delivery.FIG. 4b shows RBC EVs deliver dextran to leukemia MOLM13 cells, via FACS analysis. -
FIG. 5a is a schematic presentation of ASO delivery.FIG. 5b shows the results obtained from FACS analysis, where the MOLM13 cells were untreated or incubated with FAM ASO or with electroporated EVs (E-EVs) or with unelectroporated EVs (UE-EVs).FIG. 5c is a plot showing the results ofFIG. 5b .FIG. 5d is a diagram showing the average percentage of FAM-positive cells after treatments. In particular, the results reveal that RBC EVs deliver antisense oligonucleotides (ASO) to leukemia MOLM13 cells. -
FIG. 6a shows the results obtained from FACS analysis of AF647 fluorescence in MOLM13 cells that were untreated, incubated with Dextran AF647 (Dex-647) alone, with Dex-647 and unelectroporated RBC EVs (UE-EVs), with Dex-647 loaded Lipofectamin™ 3000 (Lipo3000), with Dex-647 loaded INTERFERin or with Dex-647 electroporated RBC EVs (E-EVs) for 24 hours.FIG. 6b shows the results obtained from FACS analysis of FAM fluorescence in MOLM13 cells that were untreated, incubated with FAM-ASO alone, with FAM-ASO and unelectroporated RBC EVs (UE-EVs), with FAM-ASO loaded Lipo3000, with FAM-ASO loaded INTERFERin or with FAM-ASO electroporated RBC EVs (E-EVs) for 24 hours. -
FIG. 7a shows the percentage of cell death/viability of MOLM13 cells after treatments with Dextran AF647 (Dex-647) alone, with Dex-647 and unelectroporated RBC EVs (UE-EVs), with Dex-647 loaded Lipofectamin™ 3000 (Lipo3000), with Dex-647 loaded INTERFERin or with Dex-647 electroporated RBC EVs (E-EVs) for 24 hours.FIG. 7b shows the percentage of cell death/viability of MOLM13 cells after treatments with FAM-ASO alone, with FAM-ASO and unelectroporated RBC EVs (UE-EVs), with FAM-ASO loaded Lipo3000, with FAM-ASO loaded INTERFERin or with FAM-ASO electroporated RBC EVs (E-EVs) for 24 hours -
FIG. 8a is a schematic presentation of miR-125b ASO delivery.FIG. 8b shows the expression of miR-125b in MOLM13 cells after treatment with unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours.FIG. 8c shows the expression of miR-125a in MOLM13 cells after treatment with unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours.FIG. 8d shows the expression of BAK1 relative to GAPDH in MOLM13 cells treated the same as inFIGS. 8b and 8c .FIG. 8e shows the number of MOLM13 cells untreated, or treated with UE-EVs or with ASO electroporated EVs as indicated. -
FIG. 9a is a schematic presentation of miR-125b ASO delivery.FIG. 9b shows the expression of miR-125b in CA1a cells after treatment with unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours.FIG. 9c shows the expression of miR-125a in CA1a cells after treatment with unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours.FIG. 9d shows the results of crystal violet staining of CA1a cells after treatments as indicated above. -
FIG. 10a is a schematic presentation of Cas9 mRNA delivery.FIG. 10b shows the levels of Cas9 mRNA in MOLM13 cells after treatment with unelectroporated EVs or with EVs that were electroporated with 5, 10 or 20 μg Cas9 mRNA, determined by qRT-PCR after 24 hours of treatment.FIG. 10c show representative images of MOLM13 cells after treatments as indicated above.FIG. 10d shows the average percentage of MOLM13 cells stained positive for HA-Cas9 protein as shown inFIG. 10 c. -
FIG. 11a is a schematic presentation of the RNA delivery.FIG. 11b shows the results obtained from FACS analysis of GFP in NOMO1-GFP cells after treatment with unelectroporated EVs or EVs electroporated with Cas9 and gRNA. -
FIG. 12a is a schematic presentation of plasmid delivery.FIG. 12b shows the results obtained from FACS analysis of GFP in 293T-eGFP cells untreated, or incubated with unelectroporated EVs (UE-EVs) or with plasmid electroporated EVs (E-EVs) as indicated.FIG. 12c shows the plot prepared from the results ofFIG. 12 b. -
FIG. 13a is a schematic presentation of an in vivo EV uptake assay.FIG. 13b shows the fluorescent images of nude mice bearing untreated tumors on the right and tumors injected with PKH26-labeled EVs on the left.FIG. 13c shows the ex vivo fluorescent images of the tumors at 72 hours post-treatment.FIG. 13d shows the total radiance efficiency (photons/second) of fluorescent signals in the tumors 24-72 hours after the injection of PKH26-labeled EVs. - The present invention relates to the field of molecular biology and genome editing. More specifically the transfer of genetic materials to recipient cells by extracellular vesicles (EVs) and the method of purification or isolation of exosomes from Red Blood Cells.
- Cells release into the extracellular environment, diverse types of membrane vesicles of endosomal and plasma membrane origin, called exosomes and microvesicles, respectively. These extracellular vesicles (EVs) represent an important mode of intercellular communication by serving as vehicles for transfer between cells of membrane and cytosolic proteins, lipids, and RNA.
- EVs secreted by many cell types contain RNAs that function to alter the phenotypes of other cells. EVs contain not only RNAs but also proteins that stabilize RNAs and facilitate the functions of RNAs in the target cells.
- EV-mediated delivery of RNAs is an attractive platform because the natural biocompatibility of EVs is the solution to overcome most in vivo delivery hurdles. EVs are generally nontoxic and non-immunogenic. They are taken up readily by many cell types but they do possess some antiphagocytic markers such as CD47 that help them to evade the phagocytosis by macrophages of the reticuloendothelial system. Moreover, EVs are able to extravasate well through the interendothelial junctions and even cross the blood-brain barrier hence, they are greatly versatile drug carriers. Of clinical value, delivery by EVs is not hampered by the multidrug resistance mechanism caused by overexpression of P-glycoproteins that tumor cells often exhibit to eliminate many chemical compounds.
- For therapeutic delivery, many research groups have attempted to produce EVs from cancer cell lines and stem cells which are very costly due to the large-scale cell culture that requires various supplements. Moreover, EVs from cancer and stem cells may contain oncogenic proteins or growth factors that promote cancer growth. EVs from plasma and blood cells are safer for cancer therapies. RBCs EVs do not contain oncogenic DNA/RNA or growth factors that are usually abundant in EVs from cancer cells or stem cells, hence, RBC EVs do not post any transformation risks to recipient cells. RBCs EVs are also nontoxic unlike synthetic transfection reagents. A recent article by Wahlgren et al describes a protocol for isolation of plasma exosomes, small EVs that are derived from multivesicular bodies, and electroporation of these exosomes with siRNAs. They demonstrated that siRNA-loaded exosomes are taken up by monocytes and lymphocytes leading to significant knockdown of the target genes. This method is probably applicable to cancer therapies however, plasma exosomes are normally very heterogeneous because they are derived from different cell types in the circulation and the yield of exosomes from plasma is low. RBCs on the other hand are homogenous as RBCs from each individual are the same.
- In the present invention, an RNA is selected to inhibit expression of a target gene by binding to a miRNA or editing the target genomic DNA. Further, there is provided a novel method for the purification of EVs from red blood cells (RBCs) and incorporation of RNAs in EVs for gene therapies against cancer, including acute myeloid leukemia and breast cancer.
- The present invention is described by reference to the following Examples, which are offered by way of illustration and are not intended to limit the invention in any manner.
- Blood samples were obtained by Red Cross from healthy donors in Hong Kong with informed consents. RBCs were separated from plasma and white blood cells by centrifugation and treated with 10 mM calcium ionophore (Sigma) overnight. The purification of EVs were optimized with multiple centrifugation steps including the removal of protein contamination using a 60% sucrose cushion (ultracentrifugation at 100,000×g) that yields a homogenous population of EVs with an average diameter of ˜140 nm. Each unit of RBCs, isolated from ˜300 ml blood, yield 7.1 mg EVs on average. These EVs are enriched in EV markers, ALIX and TSG101, as shown by Western blot analysis. They also contain hemoglobin A which is a major protein from RBCs.
-
FIG. 1a : Culture supernatants were collected from ionophore-treated human red blood cells and subjected to multiple steps of centrifugation to remove dead cells and debris. EVs were purified by ultracentrifugation with 60% sucrose cushion and washed with phosphate buffer saline (PBS) by ultracentrifugation (100,000×g).FIG. 1b : Concentrations and the size distribution of RBC EVs were measured by a Nanosight nanoparticle analyzer.FIG. 1c : Western blot analysis of ALIX, TSG101 (EV markers) and Hemoglobin A (RBC marker) relative to GAPDH in the cell lysate and EVs purified from RBCs. - Subsequently, an electroporation protocol was optimized for the RBC EVs using Dextran conjugated with Alexa Fluor® 647 (AF647, Thermo Fisher Scientific) tested at different voltages using a Gene Pulser Xcell electroporator (BioRad). Electroporated EVs were added to latex beads and analyzed for AF647 using flow cytometry. It was found that 250 V was the optimal voltage, which resulted in 93.6% AF647 positive EV-bound beads.
-
FIG. 2a : Schematic presentation of EV electroporation: 50 μg RBC EVs were mixed with 4 μg Alexa Fluor® 647 (AF647) labeled Dextran and electroporated at different voltages from 50 to 250 V. EVs were incubated with latex beads overnight and analyzed by fluorescent activated cell sorting (FACS).FIG. 2b : FACS analysis of AF647 fluorescence and forward scatter (FSC) of the beads that were incubated with electroporated EVs (E-EVs) or unelectroporated EVs (UE-EVs). The percentage of AF647 positive beads are indicated above the gates. - To measure the uptake of EVs by AML cells, the RBC-derived EVs was labelled with a fluorescent membrane dye called Bodipy® TR (Thermo Fisher). Labeled EVs were washed extensively using the sucrose cushion, mock electroporated and added to the AML MOLM13 cells. After 24 hours of incubation with EVs, Western blot analysis of MOML13 cells showed a clear uptake of Hemoglobin A (HBA) protein which was absent in the untreated cells. Importantly, treatment with RBC EVs did not affect the viability of AML cells as shown by FACS analysis. MOLM13 cells became 100% Bodipy positive after the incubation with Bodipy-labeled EVs, indicating that all the cells took up the fluorescent RBC EVs. Electroporation increased the uptake of HBA but not Bodipy by MOLM13 cells.
-
FIG. 3a : Schematic presentation of the EV uptake assay: 50 μg RBC EVs were labeled with Bodipy TR (a red fluorescent dye), washed twice, mock electroporated at 250 V, and incubated with MOLM13 cells for 24 hours.FIG. 3b : Western blot analysis of hemoglobin A (HBA) relative to GAPDH and;FIG. 3c : FACS analysis of live cells, gated based on size scatter (SSC) and forward scatter (FSC), and BODIPY fluorescence in MOLM13 cells that were untreated or incubated with electroporated EVs (E-EVs) or unelectroporated EVs (UE-EVs). - Different amounts of EVs was further electroporated with Dextran AF647 and it was found that the best delivery with 75 μg EVs resulted in 68.6% cells positive for AF647. Therefore, 75 μg EVs was used for subsequent experiments.
-
FIG. 4a : Schematic presentation of Dextran delivery: 50-100 μg RBC EVs were mixed with 4 μg Dextran AF647 and electroporated at 250 V. Electroporated EVs were incubated with MOLM13 cells for 24 hours.FIG. 4b : FACS analysis of Dextran AF647 fluorescence in MOLM13 cells that were untreated or incubated with 50-100 μg Dextran AF647 electroporated EVs (E-EVs) or 100 μg unelectroporated (UE-EVs). - Testing the delivery of RNA was started with an FAM (green fluorescent) labeled scrambled RNA oligonucleotide (Shanghai GenePharma), about 7 kDa, that is often used as a negative control antisense oligonucleotide (ASO). RBC EVs were electroporated with the FAM ASO and incubated with MOLM13 cells. After 24 hours, it was observed that ˜70% uptake of FAM ASO by MOLM13 cells. Similar uptake was observed in NOMO-1 cells, another AML cell line (data not shown).
-
FIG. 5a : Schematic presentation of ASO delivery: 75 μg RBC EVs were electroporated with 400 pmole FAM fluorescent labeled scrambled ASO (˜7 kDa) and incubated with MOLM13 cells for 24 hours.FIGS. 5b-5d : FACS analysis of FAM fluorescence in MOLM13 cells that were untreated or incubated with FAM ASO or with electroporated EVs (E-EVs) or with unelectroporated EVs (UE-EVs). The average percentage+SEM of FAM-positive cells were calculated from 3 independent experiments as shown inFIG. 5 d. - The delivery of Dextran AF647 and FAM ASO by RBC EVs was then compared with that of two commercialized lipofection reagents, Lipofectamine™ 3000 (Thermo Fisher Scientific) and INTERFERin™ (Polyplus transfection) that are commonly used for transfection of nucleic acids in mammalian cells. Consistent with previous experiments, RBC EVs delivered Dextran AF647 and FAM ASO to ˜75% MOLM13 cells. Lipofectamine™ 3000 archived only 3% and 55% delivery of Dextran AF647 and FAM ASO whereas INTERFERin archived only 2.7% and 38.7% delivery of Dextran AF647 and FAM ASO respectively in MOML13 cells. The poor delivery observed with Lipofectamine™ 3000 and INTERFERin was not a surprise since blood cells including AML cells are referred to as “difficult-to-transfect” cell types by the manufacturers. Hence, the 75% delivery efficiency archived by RBC EVs was a great improvement.
-
FIG. 6a : FACS analysis of AF647 fluorescence in MOLM13 cells that were untreated, incubated with 4 μg Dextran AF647 (Dex-647) alone, with Dex-647 and unelectroporated RBC EVs (UE-EVs), with Dex-647 loaded Lipofectamin™ 3000 (Lipo3000), with Dex-647 loaded INTERFERin or with Dex-647 electroporated RBC EVs (E-EVs) for 24 hours.FIG. 6b : FACS analysis of FAM fluorescence in MOLM13 cells that were untreated, incubated with 2 μmole FAM-ASO alone, with FAM-ASO and unelectroporated RBC EVs (UE-EVs), with FAM-ASO loaded Lipo3000, with FAM-ASO loaded INTERFERin or with FAM-ASO electroporated RBC EVs (E-EVs) for 24 hours. - Moreover, RBC EVs exhibit no toxicity to the cells in contrast to about 20-30% increase in cell death caused by the transfection using Lipofectamine™ 3000 and INTERFERin.
- The percentage of cell death was determined based on Propidium iodide (PI) staining and FACS analysis as shown in
FIG. 7a : MOLM13 cells that were untreated, incubated with 4 μg Dextran AF647 (Dex-647) alone, with Dex-647 and unelectroporated RBC EVs (UE-EVs), with Dex-647 loaded Lipofectamin™ 3000 (Lipo3000), with Dex-647 loaded INTERFERin or with Dex-647 electroporated RBC EVs (E-EVs) for 24 hours;FIG. 7b : MOLM13 cells that were untreated, incubated with 2 μmole FAM-ASO alone, with FAM-ASO and unelectroporated RBC EVs (UE-EVs), with FAM-ASO loaded Lipo3000, with FAM-ASO loaded INTERFERin or with FAM-ASO electroporated RBC EVs (E-EVs) for 24 hours. The average cell death and SEM were calculated from three independent experiments. One-way Anova test: ** P<0.05; ** P<0.01. - The therapeutic potential of RBC EVs to deliver an ASO that antagonizes the oncogenic miR-125b in AML cells was further tested. miR-125b is upregulated in different types of cancer including AML and other leukemia. It has been shown that miR-125b suppresses apoptosis by regulating multiple genes in the p53 network. miR-125b also promotes proliferation of hematopoietic stem cells and leukemia cells in both humans and mouse models. An anti-miR-125b ASO (Shanghai Gene Pharma) comprising a sequence of SEQ ID NO: 1 was loaded into RBC EVs using electroporation and treated MOLM13 cells with these EVs. After 72 hours, it was found that the level of miR-125b was suppressed by 80-95% in a dose-dependent manner. miR-125a, the homologue of miR-125b, was also suppressed by 50-80% due to the sequence similarity to miR-125b. Inhibition of miR-125 led to a significant increase in BAK1, a target of miR-125a/b which regulates apoptosis. Treatment with miR-125b ASO loaded EVs also dampened the growth of MOLM13 cells significantly after 3-4 days of incubation. Hence, the inhibition of miR-125b using ASO in RBC EVs may represent a new approach for AML treatment.
- As described here, miR-125b preferably comprises or consists of SEQ ID NO: 4 and miR-125a preferably comprises or consists of SEQ ID NO: 5. In particular, miR-125b consists of SEQ ID NO: 4 and miR-125a consists of SEQ ID NO: 5.
-
FIG. 8a : Schematic presentation of miR-125b ASO delivery: 25-100 μg RBC EVs were electroporated with 2 μmole anti-miR-125b ASO and incubated with MOLM13 cells. Anti-miR-125b ASO in this embodiment consists of SEQ ID NO: 1.FIGS. 8b-c : Expression of miR-125b and miR-125a relative to U6b snRNA in MOLM13 cells that were untreated, incubated with 100 ug unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours, as determined by Taqman qRT-PCR, presented as average and SEM.FIG. 8d : Expression of BAK1 relative to GAPDH in MOLM13 cells treated the same as inFIG. 8b .FIG. 8e : Number of MOLM13 cells untreated, or treated with UE-EVs or with ASO electroporated EVs as indicated. One-way Anova test: ** P<0.01; *** P<0.001. - Similarly, RBC EVs were tested for the delivery of miR-125b ASO to breast cancer MCF10aCA1a (CA1a) cells. The inventors observed 80-90% knockdown of miR-125a and miR-125b in CA1a cells treated with miR-125b ASO loaded EVs. As a consequence, the knockdown of miR-125s suppressed the proliferation of CA1a cells.
-
FIG. 9a : Schematic presentation of miR-125b ASO delivery: 25-50 μg RBC EVs were electroporated with 2 μmole anti-miR-125b ASO and incubated with CA1a cells.FIG. 9b-c : Expression of miR-125b and miR-125a relative to U6b snRNA in CA1a cells that were untreated, incubated with unelectroporated RBC EVs (UE-EVs), with negative control (NC)-ASO electroporated RBC EVs (E-EVs) or anti-miR-125b ASO (125b-ASO) electroporated RBC EVs for 72 hours, as determined by Taqman qRT-PCR, presented as average and SEM.FIG. 9d : Crystal violet staining of CA1a cells untreated, or treated with UE-EVs or with ASO electroporated EVs as indicated. Bar graph represent the average number of cells counted in crystal-violet stained wells (n=3). One-way Anova test: ** P<0.01. - To test the feasibility of CRISPR delivery using RBC EVs, synthetic SpCas9 mRNA (Trilink) was electroporated into RBC EVs using the protocol that was optimized for Dextran and ASO. As the result, a large amount of Cas9 mRNAs was detected in MOLM13 cells after a 24-hour incubation with the electroporated EVs, using qRT-PCR. Furthermore, using immunostaining of the HA-tag, Cas9 protein was found in the nuclei (overlapped with a nuclear stain) of ˜50% MOLM13 cells at 48-hour post-treatment. This suggests that RBC EVs can be used to deliver the CRISPR Cas9 system.
-
FIG. 10a : Schematic presentation of Cas9 mRNA delivery: RBC EVs were electroporated with Cas9 mRNA and incubated with MOLM13 cells for 24 or 48 hours.FIG. 10b : The levels of Cas9 mRNA relative to GAPDH mRNA in MOLM13 cells that were untreated, incubated with unelectroporated EVs or with EVs that were electroporated with 5, 10 or 20 μg Cas9 mRNA, determined by qRT-PCR after 24 hours of treatment. Values are presented as mean±SEM (n=3).FIG. 10c : Representative images of MOLM13 cells that were untreated, or incubated for 48 hours with unelectroporated EVs or with EVs that were electroporated with 10 μg Cas9 mRNAs. The cells were stained for HA-Cas9 protein (using green dye, not seen in black and white images) and nuclear DNA (Hoechst, blue dye, not seen in black and white images).FIG. 10d : Average percentage of MOLM13 cells stained positive for HA-Cas9 protein as shown in (c). - Subsequently, the inventors delivered Cas9 mRNA together with an anti-eGFP gRNA in RBC EVs to AML cells, NOMO1, that are labeled with eGFP. After one week, the inventors observed a complete knockout of eGFP in 32.9% NOMO1 cells. Hence, the RNAs delivered by RBC EVs were able to execute a CRISPR knockout of eGFP. As described herein, Cas9 mRNA preferably comprises or consists of SEQ ID NO: 2 and eGFP gRNA preferably comprises or consists of SEQ ID NO: 3. In particular, Cas9 mRNA consists of SEQ ID NO: 2 and eGFP gRNA consists of SEQ ID NO: 3.
-
FIG. 11a : Schematic presentation of the RNA delivery: RBC EVs were electroporated with Cas9 mRNA and anti-GFP gRNA and incubated with NOMO1-GFP cells for 7 days.FIG. 11b : FACS analysis of GFP in NOMO1-GFP cells that were untreated, incubated with unelectroporated EVs or EVs electroporated with Cas9 and gRNA. The percentages of GFP-negative cells are shown above the gate. - In addition, the delivery of plasmids by RBC EVs was also tested. RBC EVs were electroporated with two plasmids, one expressing SpCas9 and one expressing gRNA against eGFP. Electroporated EVs were incubated with human embryonic kidney HEK-293T cells that homogenously express eGFP. After 96 hours, it was found that 13.8% GFP-negative cells resulted from the EV treatment, compared to 3.52% GFP-negative in the untreated population. Treatment with electroporated EVs showed a distinct peak of GFP-negative cells that suggests a homologous knockout of eGFP by the delivery of Cas9 and gRNA plasmids. Therefore, RBC EVs are able to deliver not only RNA but also plasmid DNA for genome editing. Moreover, the delivery is applicable to HEK-293T solid cancer cells.
-
FIG. 12a Schematic presentation of plasmid delivery: RBC EVs were electroporated with Cas9 plasmid and eGFP gRNA plasmid and incubated with eGFP expressing 293T cells for 96 hours.FIGS. 12b-12c FACS analysis of GFP in 293T-eGFP cells untreated, or incubated with unelectroporated EVs (UE-EVs) or with plasmid electroporated EVs (E-EVs) as indicated. The GFP negative cells are indicated by the percentages inFIG. 12b and the arrow inFIG. 12 c. -
FIG. 13a : Schematic presentation of an in vivo EV uptake assay.FIG. 13b : Fluorescent images of nude mice bearing untreated tumors on the top and tumors injected with PKH26-labeled (red dye, not seen in black and white images) EVs on the bottom.FIG. 13c : Ex vivo fluorescent images of the tumors at 72 hours post-treatment.FIG. 13d : Total radiance efficiency (photons/second) of fluorescent signals in the tumors 24-72 hours after the injection of PKH26-labeled EVs. To determine whether the RBC EVs are taken up by tumor cells in vivo, CA1a cells were implanted in the mice, in the flank at 2 sides (FIG. 13a ). The tumor size is about 7 mm. 100 μg of PKH26 labelled EVs were then injected intratumorally. Fluorescent live imaging was done every day for 3 days (72 hours). Images of nude mice bearing untreated tumors and tumors injected with PKH26-labeled (red dye note seen in black and white images) EVs were taken (FIG. 13b ). With reference toFIG. 13c , it shows ex vivo fluorescent images of the tumors at 72 hours post-treatment and proves that PKH26-labeled EVs were taken up by tumor cells. The total radiance efficiency (photons/second) of fluorescent signals in the tumors decreased gradually 24 to 72 hours after the injection of PKH26-labeled EVs as shown inFIG. 13 d. - It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the present invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
- It will also be appreciated by persons skilled in the art that the present invention may also include further additional modifications made to the method which does not affect the overall functioning of the method.
- Any reference to prior art contained herein is not to be taken as an admission that the information is common general knowledge, unless otherwise indicated. It is to be understood that, if any prior art information is referred to herein, such reference does not constitute an admission that the information forms a part of the common general knowledge in the art, any other country.
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/825,097 US20200230259A1 (en) | 2017-08-16 | 2020-03-20 | Isolation of extracellular vesicles (evs) from red blood cells for gene therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/678,363 US10709797B2 (en) | 2017-08-16 | 2017-08-16 | Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy |
US16/825,097 US20200230259A1 (en) | 2017-08-16 | 2020-03-20 | Isolation of extracellular vesicles (evs) from red blood cells for gene therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/678,363 Continuation US10709797B2 (en) | 2017-08-16 | 2017-08-16 | Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200230259A1 true US20200230259A1 (en) | 2020-07-23 |
Family
ID=65360994
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/678,363 Active 2037-10-28 US10709797B2 (en) | 2017-08-16 | 2017-08-16 | Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy |
US16/825,097 Abandoned US20200230259A1 (en) | 2017-08-16 | 2020-03-20 | Isolation of extracellular vesicles (evs) from red blood cells for gene therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/678,363 Active 2037-10-28 US10709797B2 (en) | 2017-08-16 | 2017-08-16 | Isolation of extracellular vesicles (EVs) from red blood cells for gene therapy |
Country Status (2)
Country | Link |
---|---|
US (2) | US10709797B2 (en) |
CN (1) | CN109402176A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023077149A1 (en) * | 2021-11-01 | 2023-05-04 | Sigma-Aldrich Co. Llc | Electroporation enhancers for crispr-cas systems |
US11970718B2 (en) | 2020-01-13 | 2024-04-30 | Carmine Therapeutics Pte. Ltd. | Nucleic acid loaded extracellular vesicles |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021030769A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with nras antisense oligonucleotides |
US20230121065A1 (en) * | 2020-03-26 | 2023-04-20 | National University Of Singapore | Method of delivering nucleic acid to immune cells using rbcev |
US20230226218A1 (en) | 2020-05-11 | 2023-07-20 | Erytech Pharma | Red Cell Extracellular Vesicles (RCEVs) Containing Cargoes and Methods of Use and Production Thereof |
CN117940117A (en) * | 2021-06-30 | 2024-04-26 | 株式会社普里莫里斯治疗 | Pharmaceutical composition containing cell-derived natural or artificial nanovesicles loaded with antisense oligonucleotide-based drugs |
WO2023169594A1 (en) * | 2022-03-08 | 2023-09-14 | 中山大学 | Application of blood-derived sample in preparation of vesicles |
WO2023185697A2 (en) | 2022-03-29 | 2023-10-05 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of transthyretin amyloidosis |
CN114591905B (en) * | 2022-04-01 | 2022-09-02 | 北京大学口腔医学院 | Method for preparing apoptotic vesicles from human erythrocytes and application of apoptotic vesicles |
WO2024061296A2 (en) | 2022-09-22 | 2024-03-28 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease |
CN115887679B (en) * | 2022-11-21 | 2024-03-22 | 国家纳米科学中心 | Gene-chemotherapy nano drug co-delivery system, preparation method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9085778B2 (en) | 2006-05-03 | 2015-07-21 | VL27, Inc. | Exosome transfer of nucleic acids to cells |
US8329161B2 (en) | 2008-05-01 | 2012-12-11 | National Health Research Institutes | Red blood cell-derived vesicles as a nanoparticle drug delivery system |
EP3079726B1 (en) * | 2013-12-12 | 2018-12-05 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
US20160331686A1 (en) * | 2015-05-12 | 2016-11-17 | Clsn Laboratories, Inc. | Compositions and Methods for Yeast Extracellular Vesicles as Delivery Systems |
WO2016187717A1 (en) | 2015-05-26 | 2016-12-01 | Exerkine Corporation | Exosomes useful for genome editing |
WO2017054085A1 (en) | 2015-10-01 | 2017-04-06 | University Of Ottawa | Exosome packaging of nucleic acids |
RU2608509C1 (en) | 2016-02-11 | 2017-01-18 | Елена Сергеевна Кастарнова | Method of obtaining blood exosomes |
JP2019528674A (en) | 2016-09-30 | 2019-10-17 | セレックス ライフ サイエンシズ,インコーポレーテッド | Compositions containing exosomes loaded with proteins and methods for their preparation and delivery |
-
2017
- 2017-08-16 US US15/678,363 patent/US10709797B2/en active Active
-
2018
- 2018-08-15 CN CN201810933266.XA patent/CN109402176A/en active Pending
-
2020
- 2020-03-20 US US16/825,097 patent/US20200230259A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
AMA Style Insider (Sept 2012) downloaded from https://amastyleinsider.com/2012/09/14/around-about-approximately/ on March 24, 2023 * |
e.insights (June 2014) downloaded from https://www.editage.com/insights/scientific-writing-difference-in-meaning-of-about-around-and-approximately on March 24, 2023 * |
Zhang et al. (Erythrocyte, 2019 doi: 10.5772/intechopen.81758, pages 1-16) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11970718B2 (en) | 2020-01-13 | 2024-04-30 | Carmine Therapeutics Pte. Ltd. | Nucleic acid loaded extracellular vesicles |
WO2023077149A1 (en) * | 2021-11-01 | 2023-05-04 | Sigma-Aldrich Co. Llc | Electroporation enhancers for crispr-cas systems |
Also Published As
Publication number | Publication date |
---|---|
US20190054192A1 (en) | 2019-02-21 |
CN109402176A (en) | 2019-03-01 |
US10709797B2 (en) | 2020-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200230259A1 (en) | Isolation of extracellular vesicles (evs) from red blood cells for gene therapy | |
Usman et al. | Efficient RNA drug delivery using red blood cell extracellular vesicles | |
US10959952B2 (en) | Use of exosomes for the treatment of disease | |
RU2747722C2 (en) | RNA-guided destruction of human JC virus and other poliomaviruses | |
JP2019512458A (en) | Eradication of human JC virus and other polyoma viruses induced by RNA | |
WO2020060479A1 (en) | Cargo loaded extracellular vesicles | |
US11970718B2 (en) | Nucleic acid loaded extracellular vesicles | |
WO2018237369A2 (en) | Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection | |
JP2024059816A (en) | Methods and compositions for treating cancer using exosome-associated gene editing | |
WO2019191444A1 (en) | Use of exosomes for targeted delivery of therapeutic agents | |
US20210369858A1 (en) | Use of exosomes for targeted delivery of therapeutic agents | |
JP2021522164A (en) | Therapeutic regulation of tumor suppressors using exosomes | |
JP2021521126A (en) | Therapeutic targeting method for oncogenes using exosomes | |
US20240123034A1 (en) | Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease | |
JP6857730B2 (en) | H-1 PV expressing RNAi effectors targeting CDK9 | |
CN115887679A (en) | Gene-chemotherapy nano-drug co-delivery system, preparation method and application thereof | |
IL302316A (en) | Targeting of src-3 in immune cells as an immunomodulatory therapeutic for the treatment of cancer | |
CN117159495A (en) | Lipid nanoparticle and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |